GeoVax Labs Inc

GeoVax Labs Inc. a clinical-stage biotechnology company develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19) human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses such as Ebola Sudan Marburg and Lassa as well as therapeutic vaccines for HIV chronic Hepatitis B infections and solid tumor cancers. The company is developing GEO-CM04S1 a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin a novel patented product/technology for the treatment of solid tumors and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02 a pan-coronavirus vaccine. In addition it is also developing GEO-ZM02 a vaccine candidate which is in preclinical trial for the treatment of GEO-ZM02 a vaccine candidate which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses such as Ebola Sudan and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs Inc. was incorporated in 1988 and is headquartered in Smyrna Georgia.